Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia

Bone Marrow Transplantation

Volumn 18, Issue 1, 1996, Pages 29-34

  Demirer, T ^a,c   Petersen, F B ^b   Bensinger, W I ^a   Appelbaum, F R ^a   Fefer, A ^a   Rowley, S ^a   Sanders, J ^a   Chauncey, T ^a   Storb, R ^a   Lilleby, K ^a   Buckner, C D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Acute myelogenous leukemia; Autologous; Peripheral blood

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GRANULOCYTE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MORTALITY; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; THROMBOCYTE COUNT; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; BLOOD CELLS; BONE MARROW; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ETOPOSIDE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; LIFE TABLES; MIDDLE AGED; MITOXANTRONE; RECOMBINANT PROTEINS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; THIOGUANINE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 9544219692     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Demirer T, Buckner CD, Appelbaum FR et al. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia. Bone Marrow Transplant 1995; 15: 915-922.
2. Bensinger W, Appelbaum FR, Buckner CD et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 11: 3158-3163.
3. Rowley SD, Bensinger WI, Gooley T, Buckner CD. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994; 83: 2731-2736.
4. Demirer T, Gooley T, Buckner CD et al. Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. Bone Marrow Transplant 1995; 15: 907-913.
5. Petersen FB, Lynch MHE, Clift RA et al. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second remission. J Clin Oncol 1993; 7: 1353-1360.
6. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
7. Benyunes MC, Buckner CD, Fefer A et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12: 159-163.
8. Soiffer RJ, Murray C, Cochran K et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992; 79: 517-526.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
10. Juttner CA, To LB, Haylock DN et al. Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukemia produce prompt but incomplete hemopoietic reconstitution after high-dose melphalan or supralethal chemoradiotherapy. Br J Haematol 1985; 61: 739-745.
11. Reiffers J, Bernard P, David B et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 1986; 14: 312-315.
12. To LB, Haylock DN, Dyson PG et al. An unusual pattern of hemopoietic reconstitution in patients with acute myeloid leukemia transplanted with autologous recovery phase peripheral blood. Bone Marrow Transplant 1990; 6: 109-114.
13. Korbling M, Fliedner TM, Holle R et al. Autologous blood stem cell (ABSCT) versus purged marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant 1991; 7: 343-349.
14. Reiffers J, Korbling M, Labopin M, Gorin NC. Autologous blood stem cell transplantation versus autologous bone marrow transplantation for acute myeloid leukemia in first complete remission. Int J Cell Clon 1992; 10: 111-113.
15. Herrmann RP, O'Reilly J, Meyer BF et al. Prompt hemopoietic reconstitution following hyperthermia purged autologous marrow and peripheral blood stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplant 1992; 10: 293-295.
16. Reiffers J, Stoppa AM, Attal M et al. Autologous stem cell transplantation versus chemotherapy for adult patients with acute myeloid leukemia in first remission. The BGMT group experience. Nouv Rev Fr Hematol 1993; 35: 17-19.
17. Sanz MA, De La Rubia J, Sanz GF et al. Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplanlation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. J Clin Oncol 1993; 11: 1661-1667.
18. Mangan KF. Peripheral blood stem cell transplantation for acute and chronic myelogenous leukemias. Hematol Oncol Ann 1994; 2: 41-6.
19. Reiffers J, Stoppa AM, Attal M. Is there a place for blood stem-cell transplantation for the younger adult patient with acute myelogenous leukemia? Letter to editor. J Clin Oncol 1994; 12: 1100.
20. Szer J, Juttner CA, To LB et al. Post-remission therapy for acute myeloid leukemia with blood-derived stem cell transplantation. Results of collaborative phase II trial. Int J Cell Clon 1992; 10: 114-116.
21. Laporte JP, Gorin NC, Feuchtenbaum J et al. Relapse after autografting with peripheral blood stem cells. Lancet 1987; 2: 1393-1397.
22. Mehta J, Powles R, Singhal S, Treleaven J. Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukemia due to reinfusion of a higher number of malignant cells. Bone Marrow Transplant 1995; 15: 652-653.
23. Powles R, Mehta J, Singhal S et al. Autografting for acute myeloid leukemia in first remission: evaluation of a conditioning regimen containing melphalan and identification of modifiable treatment-related prognostic factors. Blood 1994; 84 (Suppl. 1): 718 (Abstr.).
24. Rill DR, Moen RC, Brenner MK et al. An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. Blood 1992; 79: 2694-2700.
25. Higuchi C, Thompson JA, Petersen FB et al. Toxicity and immunomodulatory effects of interleukin 2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561-2568.